Verastem Inc
$ 6.74
14.04%
07 Aug - close price
- Market Cap 610,398,000 USD
- Current Price $ 6.74
- High / Low $ 7.10 / 6.02
- Stock P/E N/A
- Book Value 0.93
- EPS -2.88
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.59 %
- ROE -7.86 %
- 52 Week High 11.25
- 52 Week Low 3.43
About
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
Analyst Target Price
$14.88
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-03-04 | 2025-11-04 | 2025-08-07 | 2025-05-13 | 2025-03-20 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-14 | 2023-11-08 |
| Reported EPS | -0.35 | -0.43 | -0.4592 | -0.54 | -0.39 | -0.79 | -0.6 | -0.88 | -0.61 | -0.98 | -1.02 | -0.71 |
| Estimated EPS | -0.46 | -0.47 | -0.4967 | -0.61 | -0.59 | -0.77 | -0.7367 | -0.82 | -1.06 | -0.87 | -0.62 | -0.79 |
| Surprise | 0.11 | 0.04 | 0.0375 | 0.07 | 0.2 | -0.02 | 0.1367 | -0.06 | 0.45 | -0.11 | -0.4 | 0.08 |
| Surprise Percentage | 23.913% | 8.5106% | 7.5498% | 11.4754% | 33.8983% | -2.5974% | 18.5557% | -7.3171% | 42.4528% | -12.6437% | -64.5161% | 10.1266% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VSTM
2026-08-07 04:41:48
Verastem Inc (VSTM) reported strong Q2 2026 net product revenues of $25.1 million, reflecting a significant rebound due to improved commercial execution for its LGSOC franchise. The company also secured a non-dilutive royalty financing agreement of up to $75 million, strengthening its balance sheet and funding operations into late 2027. Despite continued net losses, Verastem is advancing its VS 7,375 program with FDA fast track designation and encouraging preliminary clinical data, while also managing challenges in competition and clinical data translatability.
2026-08-07 00:41:48
Verastem (NASDAQ: VSTM) reported strong second-quarter results, beating analyst EPS estimates by $0.12 with earnings of $-0.310 and significantly exceeding revenue forecasts at $40.07M against an estimated $23.09M. The company's stock has seen a 20.860% increase in the last three months and a 5.160% rise over the past year. InvestingPro indicates Verastem has a "fair performance" financial health score.
2026-08-06 21:41:48
Verastem (VSTM) reported a Q2 loss of $0.35 per share, surpassing the Zacks Consensus Estimate of a $0.46 loss and exceeding prior year's loss of $0.39. The company's revenues for the quarter reached $40.08 million, significantly beating the Zacks Consensus Estimate by 73.12% and showing a substantial increase from $2.14 million a year ago. Despite beating revenue estimates, Verastem holds a Zacks Rank #4 (Sell) due to unfavorable estimate revision trends, suggesting potential underperformance in the near future.
2026-08-06 03:46:56
BlackRock, Inc. has reduced its stake in Verastem Inc (VSTM) by 7,913 shares, a 0.13% decrease, as disclosed in a recent 13G filing. The biopharmaceutical company, specializing in anticancer agents, faces significant financial and operational challenges, reflected in its low GF-Score and weak profitability metrics. Despite a recent stock price gain, long-term performance indicates underperformance and high risk for investors.
2026-08-05 20:46:56
Verastem, Inc. CEO Dan Paterson sold 1,302 shares of common stock on August 3, 2026, at a price of $5.81 per share. This transaction was executed to fulfill statutory tax withholding requirements associated with the vesting of restricted stock units (RSUs) and was conducted under a Rule 10b5-1 trading plan. Following the sale, Paterson directly holds 589,940 shares of Verastem common stock.
2026-08-04 22:40:18
Verastem Inc (VSTM) shows healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Institutional ownership is notably high, and analysts currently rate the stock as a "Buy" with a target price indicating significant upside. The stock is currently trading sideways between support and resistance levels, suggesting suitability for range-bound swing trading, despite strong fundamental performance over the last month.
